{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:05Z","timestamp":1788153485993,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K15561"],"award-info":[{"award-number":["JP21K15561"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26K03343"],"award-info":[{"award-number":["JP26K03343"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"award":["JP21K15561"],"award-info":[{"award-number":["JP21K15561"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP26K03343"],"award-info":[{"award-number":["JP26K03343"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"name":"\u201cthe Project for Submission Support\u201d of the Career Center for Female Doctors of Kansai Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, and internal radionuclide therapy is an important locoregional option for unresectable disease. This review summarizes the current landscape of transarterial radionuclide therapy for HCC and, as a translational perspective, considers how the carrier, radionuclide, and dosimetry concepts established in HCC may extend to secondary liver tumors (liver metastases). It begins with established transarterial radioembolization (TARE\/selective internal radiation therapy, SIRT) using yttrium-90 (90Y) microspheres and the shift toward personalized dosimetry and combination with systemic and immune-based therapies. It then examines alternative radionuclides and carrier systems\u2014including holmium-166 (166Ho) microspheres, iodine-131 (131I) lipiodol, rhenium-188 (188Re) lipiodol, and lutetium-177 emulsified in lipiodol (177Lu-lipiodol)\u2014from the standpoint of their physical properties, radiochemistry, theranostic potential, and preclinical and clinical evidence. Particular attention is given to 177Lu-based approaches, including their favorable beta energy, the concurrent imageable gamma emission that enables single-photon emission computed tomography (SPECT)-based dosimetry, and the potential to address post-embolization hypoxia-related radioresistance, while noting that the clinical evidence for 177Lu-lipiodol remains preclinical. The application of these platforms to colorectal and neuroendocrine liver metastases is then outlined. Finally, regulatory, radiation safety, and waste management considerations and the principal challenges to clinical translation are discussed.<\/jats:p>","DOI":"10.3390\/molecules31173030","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:24:03Z","timestamp":1788150243000},"page":"3030","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Transarterial Radionuclide Therapy for Hepatocellular Carcinoma and Other Liver Tumors: From Yttrium-90 Radioembolization to Emerging Lipiodol-Based Theranostic Approaches"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-0272","authenticated-orcid":false,"given":"Yumiko","family":"Kono","sequence":"first","affiliation":[{"name":"Department of Radiology, Kansai Medical University, Hirakata 573-1010, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kansai Medical University, Hirakata 573-1010, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kariya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kansai Medical University, Hirakata 573-1010, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-3381","authenticated-orcid":false,"given":"Noboru","family":"Tanigawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kansai Medical University, Hirakata 573-1010, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global Epidemiology of NAFLD-Related Hepatocellular Carcinoma: Trends, Predictions, Risk Factors and Prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.56782\/pps.236","article-title":"Differences in the Course of Hepatocellular Carcinoma Depending on the DAA Treatment","volume":"22","author":"Lembas","year":"2024","journal-title":"Prospects Pharm. Sci."},{"key":"ref_6","unstructured":"B\u00e9, M.-M., Chist\u00e9, V., Dulieu, C., Kellett, M.A., Mougeot, X., Browne, E., Baglin, C., Chechev, V.P., Egorov, A., and Kuzmenko, N. Table of Radionuclides (Monographie BIPM-5), Bureau International des Poids et Mesures. Available online: https:\/\/www.bipm.org\/en\/publications\/monographies."},{"key":"ref_7","unstructured":"National Nuclear Data Center (2026, August 25). NuDat 3.0: Nuclear Structure and Decay Data, Available online: https:\/\/www.nndc.bnl.gov\/nudat3\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for Targeted Radionuclide Therapy: Available Options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Uccelli, L., Martini, P., Urso, L., Ghirardi, T., Marvelli, L., Cittanti, C., Carnevale, A., Giganti, M., Bartolomei, M., and Boschi, A. (2022). Rhenium Radioisotopes for Medicine, a Focus on Production and Applications. Molecules, 27.","DOI":"10.3390\/molecules27165283"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-9966-29-70","article-title":"Holmium-166 Radioembolization for the Treatment of Patients with Liver Metastases: Design of the Phase I HEPAR Trial","volume":"29","author":"Smits","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2349\/biij.2.3.e40","article-title":"Radionuclide Therapy of Hepatocellular Carcinoma","volume":"2","author":"Sundram","year":"2006","journal-title":"Biomed. Imaging Interv. J."},{"key":"ref_12","unstructured":"Boston Scientific (2021). TheraSphere Yttrium-90 Glass Microspheres: Instructions for Use\/Package Insert, Boston Scientific. U.S. Food and Drug Administration Humanitarian Device Exemption H980006."},{"key":"ref_13","unstructured":"Sirtex Medical (2025). SIR-Spheres Yttrium-90 Resin Microspheres: Instructions for Use, Sirtex Medical."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","article-title":"The Development, Commercialization, and Clinical Context of Yttrium-90 Radiolabeled Resin and Glass Microspheres","volume":"1","author":"Westcott","year":"2016","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","article-title":"Holmium-166 Radioembolisation in Patients with Unresectable, Chemorefractory Liver Metastases (HEPAR Trial): A Phase 1, Dose-Escalation Study","volume":"13","author":"Smits","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"Procedure Guidelines for Treatment of Liver Cancer and Liver Metastases with Intra-Arterial Radioactive Compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1148\/radiol.2432051246","article-title":"Inoperable Hepatocellular Carcinoma: Transarterial 188Re-HDD-Labeled Iodized Oil for Treatment\u2014Prospective Multicenter Clinical Trial","volume":"243","author":"Kumar","year":"2007","journal-title":"Radiology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ijrobp.2007.05.009","article-title":"Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study","volume":"69","author":"Bernal","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Garin, E., Palard, X., Rolland, Y., Le Sourd, S., Lepareur, N., Ardisson, V., Bouvry, C., Laffont, S., Campillo-Gimenez, B., and Bellissant, E. (2023). 188Re-SSS Lipiodol Radioembolization in Hepatocellular Carcinoma: Lip-Re-01 Phase 1 Study. Cancers, 15.","DOI":"10.3390\/cancers15082245"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0043-1764306","article-title":"188Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)\u2014A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy","volume":"22","author":"Kumar","year":"2023","journal-title":"World J. Nucl. Med."},{"key":"ref_21","first-page":"539","article-title":"Preparation of 177Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study","volume":"25","author":"Subramanian","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11307-025-02016-1","article-title":"Evaluation of 177Lu-Labeled Lipiodol as a Targeted Radionuclide Therapy for Hepatocellular Carcinoma in a Preclinical Xenograft Model","volume":"27","author":"Kono","year":"2025","journal-title":"Mol. Imaging Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40658-023-00524-z","article-title":"Dealing with Dry Waste Disposal Issues Associated with 177mLu Impurities: A Long-Term Challenge for Nuclear Medicine Departments","volume":"10","author":"Prevot","year":"2023","journal-title":"EJNMMI Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2191-219X-3-11","article-title":"Assessment of Acquisition Protocols for Routine Imaging of Y-90 Using PET\/CT","volume":"3","author":"Carlier","year":"2013","journal-title":"EJNMMI Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Elschot, M., Vermolen, B.J., Lam, M.G.E.H., de Keizer, B., van den Bosch, M.A.A.J., and de Jong, H.W.A.M. (2013). Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055742"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus Standard Dosimetry Approach of Selective Internal Radiation Therapy in Patients with Locally Advanced Hepatocellular Carcinoma (DOSISPHERE-01): A Randomised, Multicentre, Open-Label Phase 2 Trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-Term Overall Survival after Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinoma: Updated DOSISPHERE-01 Analysis","volume":"65","author":"Garin","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mahvash, A., Chartier, S., Turco, M., Habib, P., Griffith, S., Brown, S., and Kappadath, S.C. (2022). A Prospective, Multicenter, Open-Label, Single-Arm Clinical Trial Design to Evaluate the Safety and Efficacy of 90Y Resin Microspheres for the Treatment of Unresectable HCC: The DOORwaY90 Study. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02204-1"},{"key":"ref_31","unstructured":"U.S. Food and Drug Administration (2026, August 25). Summary of Safety and Effectiveness Data (SSED): SIR-Spheres Y-90 Resin Microspheres; PMA P990065\/S014; Approved 1 July 2025, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?ID=P990065S014."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver Disease Induced by Radioembolization of Liver Tumors: Description and Possible Risk Factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic Factors and Prevention of Radioembolization-Induced Liver Disease","volume":"57","author":"Chopitea","year":"2013","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-Induced Liver Disease: A Systematic Review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","article-title":"Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma","volume":"118","author":"Yeo","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e005457","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after Selective Internal Radiation Therapy for the Treatment of Hepatocellular Carcinoma: A Phase 2, Single-Arm Study","volume":"10","author":"Matilla","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","article-title":"A Pilot Study of Pembrolizumab in Combination with Y90 Radioembolization in Subjects with Poor Prognosis Hepatocellular Carcinoma","volume":"29","author":"Yu","year":"2024","journal-title":"Oncologist"},{"key":"ref_38","unstructured":"ClinicalTrials.gov (2026, June 21). A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination with Durvalumab and Bevacizumab Therapy in People with Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90); Phase 2; Sponsor: AstraZeneca; NCT06040099, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06040099."},{"key":"ref_39","unstructured":"ClinicalTrials.gov (2026, June 21). Atezolizumab and Bevacizumab in Combination with Y-90 Radioembolization in HCC for Liver Transplant (Bridging or Downstaging); NCT07059494, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07059494."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s00270-022-03187-y","article-title":"Holmium-166 Radioembolization: Current Status and Future Prospective","volume":"45","author":"Stella","year":"2022","journal-title":"CardioVasc. Interv. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2967\/jnumed.117.197194","article-title":"Efficacy of Radioembolization with 166Ho Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study","volume":"59","author":"Prince","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","article-title":"Additional Holmium-166 Radioembolisation after Lutetium-177-DOTATATE in Patients with Neuroendocrine Tumour Liver Metastases (HEPAR PLuS): A Single-Centre, Single-Arm, Open-Label, Phase 2 Study","volume":"21","author":"Braat","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2967\/jnumed.122.263823","article-title":"Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study","volume":"63","author":"Reinders","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(98)06475-7","article-title":"Adjuvant Intra-Arterial Iodine-131-Labelled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomised Trial","volume":"353","author":"Lau","year":"1999","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/SLA.0b013e3181571047","article-title":"Adjuvant Intra-Arterial Iodine-131-Labeled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomized Trial\u2014Update on 5- and 10-Year Survival","volume":"247","author":"Lau","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2967\/jnumed.113.131367","article-title":"Adjuvant Intraarterial Lipiodol or 131I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial","volume":"55","author":"Dumortier","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_47","first-page":"1782","article-title":"Randomized Controlled Trial for Hepatocellular Carcinoma with Portal Vein Thrombosis: Intra-Arterial Iodine-131-Iodized Oil versus Medical Support","volume":"35","author":"Raoul","year":"1994","journal-title":"J. Nucl. Med."},{"key":"ref_48","first-page":"1156","article-title":"Prospective Randomized Trial of Chemoembolization versus Intra-Arterial Injection of 131I-Labeled Iodized Oil in the Treatment of Hepatocellular Carcinoma","volume":"26","author":"Raoul","year":"1997","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lepareur, N., Lac\u0153uille, F., Bouvry, C., Hindr\u00e9, F., Garcion, E., Ch\u00e9rel, M., Noiret, N., Garin, E., and Knapp, F.F. (2019). Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00132"},{"key":"ref_50","first-page":"1326","article-title":"188Re-HDD\/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis","volume":"46","author":"Lambert","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00259-023-06155-x","article-title":"[177Lu]Lu-PSMA-617 Theranostic Probe for Hepatocellular Carcinoma Imaging and Therapy","volume":"50","author":"Lu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-Line Selective Internal Radiotherapy plus Chemotherapy versus Chemotherapy Alone in Patients with Liver Metastases from Colorectal Cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A Combined Analysis of Three Multicentre, Randomised, Phase 3 Trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial (EPOCH)","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5104082","DOI":"10.1155\/2020\/5104082","article-title":"Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases","volume":"2020","author":"Tsang","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11864-023-01152-6","article-title":"Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy","volume":"24","author":"Rabei","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_56","unstructured":"U.S. Nuclear Regulatory Commission (2022). Notification of Issuance of Revision of Licensing of Lutetium-177 (STC-22-074), U.S. NRC. ADAMS Accession No. ML22318A151."},{"key":"ref_57","unstructured":"Council of the European Union (2013). Council Directive 2013\/59\/Euratom Laying Down Basic Safety Standards for Protection Against the Dangers Arising from Exposure to Ionising Radiation, Council of the European Union."},{"key":"ref_58","unstructured":"International Atomic Energy Agency (2019). Predisposal Management of Radioactive Waste from the Use of Radioactive Material in Medicine, Industry, Agriculture, Research and Education, IAEA. IAEA Safety Standards Series No. SSG-45."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:27:22Z","timestamp":1788150442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":58,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["molecules31173030"],"URL":"https:\/\/doi.org\/10.3390\/molecules31173030","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}